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Background: Huntington's Disease (HD) is a fatal hereditary neurodegenerative disease caused by the
accumulation of mutant huntingtin protein (Htt) containing an expanded polyglutamine (polyQ) tract. Activation of
the channel responsible for the inositol-induced Ca2+ release from ensoplasmic reticulum (ER), was found to
contribute substantially to neurodegeneration in HD. Importantly, chemical and genetic inhibition of inositol
1,4,5-trisphosphate (IP3) receptor type 1 (IP3R1) has been shown to reduce mutant Htt aggregation.
Results: In this study, we propose a novel regulatory mechanism of IP3R1 activity by type III intermediate filament
vimentin which sequesters the negative regulator of IP3R1, IRBIT, into perinuclear inclusions, and reduces its
interaction with IP3R1 resulting in promotion of mutant Htt aggregation. Proteasome inhibitor MG132, which
causes polyQ proteins accumulation and aggregation, enhanced the sequestration of IRBIT. Furthermore we found
that IRBIT sequestration can be prevented by a rho kinase inhibitor, Y-27632.
Conclusions: Our results suggest that vimentin represents a novel and additional target for the therapy of polyQ
diseases.
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Huntington's disease (HD) is an autosomal-dominant
neurodegenerative disorder caused by CAG repeat ex-
pansion coding for a polyglutamine (polyQ) sequence in
the N-terminal region of the huntingtin protein (Htt).
The expansion of more than 36 repeats causes misfold-
ing of the gene product huntingtin resulting in a toxic
gain-of-function [1]. Clinically, HD is characterized by
chronic and progressive involuntary choreiform move-
ments, mood disorders, cognitive impairment, and be-
havioral changes [2,3]. A prominent feature of this
disease is progressive neurodegeneration, with neuronal
intranuclear and cytoplasmic accumulation of aggre-
gated polyQ protein [4,5]. HD pathomechanism involves
a broad scale of events including dysregulation of* Correspondence: mikosiba@brain.riken.jp; nukina@brain.riken.jp
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reproduction in any medium, provided the ortranscription and gene expression, impairment of axonal
transport and synaptic transmission and impairment of
the ubiquitin proteasome system (UPS) [6,7]. Mitochon-
drial dysfunction leading to induction of mitochondrial
apoptotic pathway has also been described in HD with
Ca2+ mishandling and suppression of energy metabolism
[8,9]. Despite an enormous effort in elucidating the
pathogenesis of this disorder, effective therapies for HD
have not yet been found.
Vimentin is a 57 kDa type III intermediate filament
(IF) found in cells of mesenchymal origin [10,11]. While
widely expressed in embryos, vimentin is replaced by
other major classes of IFs in cells during terminal differ-
entiation [12,13]. In the adult brain, vimentin expression
is mostly restricted to some subpopulations of glial and
vascular endothelial cells under physiological conditions
[12-14]. Importantly, it has been found that vimentin ex-
pression is re-activated in mature neurons affected by
Alzheimer’s disease or traumatic injury [15,16].
Degradation of misfolded proteins has been shown
partly mediated by UPS. The components of UPS in-
cluding the 26S proteasome and ubiquitin as well as heattd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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When UPS is overloaded by misfolded proteins and/or it
is chemically inhibited, the centromeric accumulation of
these proteins increases forming aggresomes which may
represent a general cellular response to dysfunctional or
damaged polyubiquitinated proteins accumulation [18,19].
Another evidence of the association of aggresome forma-
tion with the accumulation and degradation of misfolded
proteins has come from studies, where pathogenic polyQ
proteins Htt and atrophin-1 formed inclusions at centro-
somes which were surrounded by vimentin [20,21].
Vimentin is recruited to the aggresomes during UPS dys-
function and forms a cage-like structure surrounding the
pericentriolar focus of aggregated protein [19].
The role of aggresomes and especially the vimentin
cage in polyQ diseases progression is not clear. We
hypothesized that vimentin may play a major role in
polyQ proteins accumulation and aggregation and that
vimentin cage may immobilize or trap not only the UPS
components and chaperones, but also other important
proteins at the centrosomic inclusions and thus prevent-
ing their functions elsewhere in the cell. We found that
one of such proteins, IP3R1-interacting protein released
with IP3 (IRBIT) is also sequestered by vimentin. IRBIT
has numerous regulatory functions among which the
IP3R1 activity regulation is most intriguing [22,23].
IRBIT binds to IP3-binding core domain of IP3R1 acting
as a competitor to IP3 [23,24]. Absence of IRBIT sensi-
tizes IP3R1 to IP3, which leads to an increase in Ca2+ re-
lease from endoplasmic reticulum [23].
IP3R1 was found to be involved in polyQ diseases
pathomechanism [25,26]. In planar lipid bilayer reconsti-
tution experiments and in primary cultures of rat striatal
medium spiny neurons, IP3R1 was sensitized to IP3 by
mutant forms of Htt, while normal Htt had no effect.
This finding confirmed that the activation of IP3R1 by
expanded polyQ Htt is a contributing factor of Ca2+ sig-
naling alteration and neuronal degeneration in HD [25].
Knock-down of IP3R1 or direct chemical inhibition of
the IP3R1 activity also reduced polyQ proteins accumu-
lation and aggregation [27] and cell death [28].
Here we introduce a novel pathway of IP3R1 activity
regulation, where vimentin is able to sequester IRBIT
from interaction with IP3R1. Moreover, IRBIT sequestra-
tion was enhanced by the phosphomimetic S71E/S38E
vimentin mutant (E2; Ser71 and Ser38 replaced with
Glu). Phosphorylation of Ser71 and Ser38 is mediated by
rho-associated kinases (ROCKs) [29,30]. ROCKs are Ser/
Thr protein kinases, which were found to be down-
stream targets of the small GTPase RhoA [31,32]. In the
mammalian system, ROCKs consist of two isoforms,
ROCK1 and ROCK2 [31]. They are important regulators
of cell growth, migration, and apoptosis via control of
actin cytoskeletal assembly [33]. Blocking the RhoA/ROCK pathway has been shown to inhibit the polyQ
protein aggregation and decrease its toxicity in cellular
and Drosophila models of HD [34]. ROCK1 and protein
kinase C-related protein kinase-2 (PRK-2) have been
identified to be the mediators of aggregation reduction
by the well-known ROCK inhibitor Y-27632 [35]. More-
over, a downstream effector of ROCK1, actin-binding
factor profilin, was reported to inhibit the mutant Htt
aggregation by direct interaction via its polyproline-
binding domain [36]. Previously, we have reported that
Y-27632 treatment also reduced aggregation of several
other polyQ proteins without polyproline tracts, thus
possibly affecting additional targets [37,38]. Here we
show that vimentin may represent one of the mediators
of ROCK inhibition-dependent reduction of pathogenic
polyQ proteins aggregation via modulation of IP3R1 ac-
tivity by IRBIT.
Results and discussion
Effect of vimentin levels and phosphorylation on polyQ
aggregation
To investigate the role of vimentin in polyQ Htt proces-
sing, we considered several clues. Firstly, UPS impair-
ment is thought to contribute to the severity of HD
[6,7]. Vimentin creates cages around aggresomes, which
are formed in response to accumulation of misfolded
proteins and UPS dysfunction [19]. Secondly, vimentin
is phosphorylated by several kinases, including ROCKs
[29,30]. Thirdly, ROCK1 is activated by dopamine
through dopamine D2 receptor (D2R)-specific pathway
potentiating the glutamate excitotoxicity in HD [39,40]
and the genetic and chemical inhibition of Rho/ROCK
signaling pathway reversed dopamine/D2R-mediated
cellular pathology [40]. Importantly, ROCK inhibitor
Y-27632 reduced mutant Htt levels and aggregation both
in vitro [34,37] and in vivo and improved motor impair-
ment in R6/2 HD mouse model [41].
We overexpressed RFP or RFP-vimentin in 16Q
and 60Q and 150Q Neuro2a cells. We observed that
vimentin accumulated at perinuclear regions and formed
cage-like structures around tNHtt-60Q-EGFP and tNHtt-
150Q-EGFP inclusions in 60Q and 150Q Neuro2a cells
while RFP exerted diffuse distribution in all cell lines
(Figure 1A and Additional file 1: Figure S1). This con-
firmed the previously reported colocalization of vimentin
with pathogenic polyQ protein inclusions [17,18].
Next we asked whether vimentin could modulate mu-
tant Htt aggregation. We found that over-expression of
RFP-vimentin in 150Q Neuro2a cells dramatically
increased the accumulation of insoluble Htt. Accumula-
tion of the soluble form was also observed and could be
the result of enhanced aggresomes formation leading to
suppression of UPS activity under this condition. Vimen-
tin knock-down, on the other hand reduced the mutant
Figure 1 Vimentin modifies mutant Htt aggregation. A. Representative confocal images show distribution of normal (16Q) and pathogenic
(60Q and 150Q) tNHtt (green) and RFP or RFP-vimentin (red) in inducible tNHtt-polyQ-EGFP Neuro2a cells. Note the cages formed by vimentin in
60Q and 150Q Neuro2a cells. Nuclei were stained with DAPI (blue). Scale bar, 5 μm. B. RFP-vimentin expression increased and vimentin knock-
down reduced polyQ aggregation and levels of total mutant Htt in 150Q Neuro2a cells as compared to the control. C. The effect of RFP-vimentin
on Htt levels is polyQ length-dependent. While tNHtt-60Q-EGFP and tNHtt-150Q-EGFP accumulated as the insoluble forms at the gel top, tNHtt-
16Q-EGFP levels remained unchanged upon RFP-vimentin transfection.
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of vimentin is polyQ length-dependent, we over-
expressed RFP-vimentin in 16Q, 60Q and 150Q Neuro2a
cells. Vimentin appeared to act specifically on mutant
Htt, as the levels of tNHtt-16Q-EGFP remained un-
changed while the accumulation of insoluble pool of the
pathogenic Htt forms increased (Figure 1C).
Vimentin has been shown phosphorylated by ROCK at
Ser71 and Ser38 amino residues [29,30] and we con-
firmed this fact, as treatment of Neuro2a cells with the
ROCK inhibitor Y-27632 reduced the phosphorylation atthese sites (Figure 2A). We transfected stable RFP-
vimentin Neuro2a cells with tNHtt-60Q-EGFP and trea-
ted them with Y-27632. Interestingly, we detected a
modified subcellular distribution of stably expressed
RFP-vimentin in Neuro2a cells treated with Y-27632
(Figure 2B). In the untreated cells, RFP-vimentin formed
cage-like structures around tNHtt-60Q-EGFP inclusions
while the Y-27632 treatment changed the localization of
RFP-vimentin to neurites (Figure 2B). This observation
suggested that vimentin phosphorylation by ROCK
might influence polyQ aggregation.
Figure 2 Vimentin affects the mutant Htt inclusion formation in 150Q Neuro2a cells and mediates the effect of Y-27632. A. Immunoblot
demonstrating inhibition of vimentin phosphorylation at Ser71 and Ser38 by ROCK inhibitor Y-27632 (20 μM) in Neuro2a cells. B. tNHtt-60Q-EGFP
(green) was transfected to Neuro2a cells stably expressing RFP-vimentin (red). Treatment of these cells with 20 μM Y-27632 resulted in filament-
like distribution of vimentin and disruption of vimentin cages observed around tNHtt-60Q-EGFP inclusions in the untreated cells. Nuclei were
stained with DAPI (blue). Scale bar, 15 μm. C. The effect of Y-286432 on polyQ inclusion formation depends on vimentin level (high vimentin
levels enhance inclusion formation). 150Q Neuro2a cells were transfected with vimentin shRNA and 48 hrs later, the cells were induced and
treated with 20 μM Y-27632. After 24 hrs, cells were fixed and the inclusion formation was quantified by ArrayScan. *p= 0.00003, ** p= 0.0012,
***p= 0.00003, ****p= 0.0018. D. The effect of vimentin knock-down and Y-27632 on polyQ cytotoxicity. Cells were incubated with PI and the PI-
positivity was quantified by ArrayScan. *p= 0.0022, ** p= 0.002, ***p= 0.001, ****p= 0.017. E. The effect of Y-286432 on polyQ inclusion formation
is dependent on vimentin phosphorylation (vimentin phosphorylation enhances inclusion formation). 150Q Neuro2a cells were transfected with
RFP, WT and phospho-mutant (A2 and E2) forms of RFP-vimentin. Cells were induced and treated with 20 μM Y-27632 for 24 hrs, fixed and
analyzed by ArrayScan. *p= 0.00016, **p= 0.0003, ***p= 0.0004, ^p= 0.0021, ^^p= 0.018, #p= 0.04, ##p= 0.022. F. The effect of vimentin over-
expression and Y-27632 on polyQ-induced cell death. Dead cells were detached and removed during samples preparation for analysis. Cells that
remained attached were counted by ArrayScan. *p= 0.049, **p= 0.008, ^p= 0.044, ^^p= 0.045, #p= 0.032, ##p= 0.034. Bars in C-F represent relative
mean values ± s.d. from three independent experiments, with levels under control conditions normalized to a value of 1.
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Htt aggregation, we transfected the 150Q Neuro2a cells
with vimentin shRNA and counted the inclusions on a
cell-to-cell basis by ArrayScan. Vimentin knock-down
reduced the number of the cells with inclusions by 39%
(Figure 2C). Treatment of the 150Q Neuro2a cells with
20 μM Y-27632 reduced the polyQ aggregation by 62%,
similarly to the previously reported effect in these cells[37]. Vimentin knock-down significantly decreased the
effect of Y-27632 to 40% (22% difference as compared to
the 62% aggregation reduction in the non-transfected
cells) (Figure 2C), suggesting that the effect of Y-27632 is
partly mediated through the inhibition of the phosphory-
lation of vimentin. Importantly, vimentin knock-down also
significantly decreased the number of propidium iodide
(PI)-positive 150Q Neuro2a cells indicating reduction of
Figure 3 Vimentin influences the IRBIT-IP3R1 interaction by
sequestering IRBIT in perinuclear inclusions. A. HeLa cells were
transfected with RFP or tested forms of RFP-vimentin. 24 hrs later,
cells were lysed and immunopreciptitation was performed using
10A6 anti-IP3R1 antibody. For immunoblotting, KM1112 anti-IP3R1,
anti-IRBIT and anti-RFP antibodies were used. B. Quantification of
IRBIT-IP3R1 interaction. The densities of immunoprecipitated IRBIT
were normalized to the densities of corresponding
immunoprecipitated IP3R1. *p= 0.0002, **p= 0.009, ***p= 0.0001,
#p= 0.0017, ##p= 0.029, ###p= 0.0009. Bars represent relative mean
values ± s.d. from three independent experiments, with levels of
IRBIT-IP3R1 interaction under control conditions normalized to a
value of 1. C. Representative confocal images show distribution of
immobile fraction of IRBIT in presence of RFP or tested RFP-vimentin
forms. Neuro2a cells were transfected with RFP or RFP-vimentins,
24 hrs later permeabilized with saponin and immunostained for
endogenous IRBIT (green). Fluorescence of RFP (red) and DAPI (blue)
are also shown. Note that RFP was washed out from cells during
saponin permeabilization. Scale bar, 5 μm.
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anti-aggregation effect of WT and phospho-mutants of
vimentin in 150Q Neuro2a cells. Ser71 and Ser38 were
substituted with phosphomimetic Glu (E2 mutant) or
non-phosphorylated Ala (A2 mutant) amino acid residues.
Over-expression of any of the RFP-vimentin form in-
creased inclusion formation in 150Q Neuro2a cells. The
E2 and A2 mutants had significantly stronger and weaker
effect, respectively, as compared to the WT vimentin.Importantly, the effect of Y-27632 was abolished in cells
expressing vimentin mutants (Figure 2E). WT and E2
mutants significantly increased the number of dead cells
removed from the wells during the preparation of the sam-
ples for ArrayScan analysis while A2 vimentin did not have
significant effect as compared to the control cells trans-
fected with RFP (Figure 2F). These results confirmed that
the effect of ROCK inhibitor Y-27632 on the mutant Htt
aggregation and cytotoxicity is mediated by the phosphory-
lation status of vimentin and partly depends on the levels
of this protein.Vimentin sequesters IRBIT and decreases its interaction
with IP3R1
Next, we aimed to identify the mechanism, by which
vimentin levels and phosphorylation modifies accumula-
tion and aggregation of pathogenic Htt. Our hypothesis
on vimentin affecting polyQ aggregation in cooperation
with IP3R1 was based on several studies. Firstly, the
phosphorylation dynamics plays an important role in
vimentin network reorganization and it changes vimen-
tin affinity to its interacting partners, mostly regulatory
proteins, and their spatial distribution [42]. Secondly,
IP3R1 is directly involved in mutant Htt inclusion for-
mation [27]. Thirdly, there has been reported a crosstalk
between IP3R1 activity and intermediate filaments [43].
It has also been suggested that IP3Rs may be involved in
the mechanism underlying the potentiating action of the
Y-27632 in neurite outgrowth [44], which includes modi-
fications of vimentin dynamics [45].
As inhibiting IP3R1 activity reduced polyQ Htt accu-
mulation and aggregation [27], it was feasible to assume
that stimulation of IP3R1 can contribute to polyQ aggre-
gation. While exploring this hypothesis, we focused on
one of the IP3R regulatory proteins, IRBIT [46]. IRBIT
Figure 4 Vimentin phosphorylation affects IRBIT subcellular
distribution. Effect of ROCK and UPS inhibitors. Representative
confocal images show subcellular distribution of IRBIT in presence of
RFP or tested RFP-vimentin forms. Neuro2a cells were transfected
and treated as indicated for 24 hrs. Cells were fixed, permeabilized
and immunostained for enogenous IRBIT (green). A. Control
untreated cells (DMSO, 1/1000). B. Cells treated with 20 μM Y-27632.
C. Cells treated with 5 μM MG132. Fluorescence of RFP (red) and
DAPI (blue) are also shown. Scale bar, 5 μm.
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HeLa cells were transfected with RFP or tested forms of
RFP-vimentin and 24 hrs later, immunoprecipitation
using anti-IP3R1 antibody was performed. We found
that over-expression of RFP-vimentin suppressed the
IRBIT-IP3R1 interaction by 47% (Figure 3A, B). As the
phosphorylation status of vimentin turned out important
for the extent of the polyQ aggregation modification
(Figure 2), we also wondered how the vimentin phospho-
mutants A2 and E2 would influence the IRBIT-IP3R1
interaction. As expected, the A2 mutant reduced this
interaction only by 18% while the E2 form of vimentin
suppressed the IRBIT binding to IP3R1 by 63% as com-
pared to the control (Figure 3A, B). These findings sug-
gested that both the levels and phosphorylation status
of vimentin are determining factors in suppressing the
IRBIT-IP3R1 interaction and therefore influencing the
activity of IP3R1.
To support our observations, we investigated the
localization of the membrane-bound fraction of IRBIT
in the presence of vimentin. We transfected Neuro2a
cells with RFP or with tested RFP-vimentin forms.
The cells were then permeabilized with saponin to re-
move the soluble cytosolic proteins, and subjected to
confocal microscopy with immunostained IRBIT. While
RFP, as a soluble protein not interacting with cytoskel-
eton or membranes, was not detected in the samples,
RFP-vimentin was present and displayed different
localization patterns depending on the amino acids at
positions 71 and 38. WT and particularly E2 vimentin
formed perinuclear cage-like structures, while the A2
mutant was dispersed with mostly filamentous-like dis-
tribution (Figure 3C). Importantly, IRBIT appeared
trapped inside the structures formed by WT and E2
RFP-vimentins with almost exclusive localization of
IRBIT within these inclusions in the E2-transfected cells.
The A2 mutant, on the other hand, did not affect the
IRBIT distribution so markedly as compared to the con-
trol RFP-transfected cells (Figure 3C). These observa-
tions are in agreement with the data obtained by IRBIT-
IP3R1 co-immunoprecipitation (Figure 3A, B).
Modification of IRBIT sequestration by ROCK and UPS
inhibition
The next question was whether the distribution of tested
RFP-vimentins and IRBIT could be modified upon
ROCK or UPS inhibition by Y-27632 or MG132 treat-
ment, respectively. In the untreated cells, E2 vimentin
accumulated in perinuclear inclusions and colocalized
with IRBIT. Diffuse cytoplasmic staining of IRBIT was
markedly reduced as compared to control cells indica-
ting that IRBIT was recruited by E2 mutant to the
aggresome-like inclusions. The A2 mutant exerted
filamentous-like distribution with most of IRBITremaining diffuse. The distribution of WT vimentin
appeared as an intermediate pattern between the
mutants (Figure 4A). When cells were treated with
Y-27632, the WT form gained a filamentous distribution
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tion) and lost the colocalization with IRBIT seen in the
non-treated cells (Figure 4B). The unphosphorylated A2
and phosphomimetic E2 mutants were resistant to
Y-27632 treatment (target serine amino acids mutated)
and retained their distributions with A2 being filamen-
tous-like, and E2 forming perinuclear aggresome-like
inclusions and trapping IRBIT. These results suggest
that the subcellular distribution of IRBIT regulated by
vimentin is under the control of ROCK through phos-
phorylation of Ser71 and Ser38.
UPS inhibition has been shown to induce the forma-
tion of aggresomes [20]. Upon treatment with MG132,
we observed IRBIT accumulation in aggresome-like
structures even in control cells transfected with RFP.
UPS inhibition in cells expressing WT RFP-vimentin
caused its complete relocation into perinuclear inclu-
sions and IRBIT accumulation in this location was mark-
edly enhanced as compared to control cells, resembling
the effect of E2 RFP-vimentin (Figure 4C). In the E2-
transfected cells, this distribution of vimentin and IRBIT
was observed under all conditions (Figure 4A-C). Unex-
pectedly, the A2 mutant appeared to be resistant to
MG132 treatment, retained its filamentous structure and
prevented the accumulation of IRBIT in the aggresome-
like inclusions (Figure 4C). This observation suggested a
novel role for vimentin as a component actively regulat-
ing aggresome formation or at least sequestering and
immobilizing certain proteins within this structure. We
hypothesize that when the vimentin cage is not fully
formed, some of the proteins can escape from aggre-
somes and at least partially fulfill their function at the
physiological subcellular locations.
Overall, our results suggest that IRBIT can be seques-
tered by vimentin to perinuclear aggresome-like struc-
tures. The extent of sequestration appears to depend
not only on the levels but also on the phosphorylation
status of vimentin. All the above-discussed observa-
tions on vimentin-IRBIT connection were obtained in
the absence of mutant Htt to avoid possible influence of
this pathogenic protein, as mutant Htt sensitizes IP3R1
to IP3 via direct binding to the C-terminal part of IP3R1
[25,39] and augmenting aggresome formation [19].
Effect of vimentin on mutant Htt aggregation is mediated
by IRBIT
To test the relevance of the vimentin-IRBIT pathway to
HD, we examined whether IRBIT could be a mediator of
the modifying effect of vimentin on mutant Htt aggrega-
tion. We over-expressed WT, A2 or E2 RFP-vimentin in
150Q Neuro2a cells with or without knocking-down
IRBIT, induced the tNHtt-150Q-EGFP expression and
analyzed the inclusion formation by ArrayScan. Knock-
down of IRBIT increased the inclusion formation almosttwice (1.95-fold) in the RFP-expressing cells. The effect
of IRBIT knock-down was enhanced by all forms of
vimentin with E2 mutant having the strongest effect fol-
lowed by WT and the A2 mutant with 8.37-, 6.65- and
5.57-fold increase of inclusion formation, respectively
(Figure 5A). Over-expression of IRBIT, in contrary,
reduced the inclusion formation in 150Q Neuro2a cells
by 35%. The effect of high IRBIT levels was relatively
reduced in the presence of WT and A2 vimentin, with
23% and 28% difference, respectively, between the single
and double transfections. E2 vimentin, on the other
hand, abolished the effect of IRBIT with no difference
between the E2 and E2 + IRBIT conditions (Figure 5C).
Examples of compound images generated by ArrayScan
representing each experimental condition are shown in
Figure 5B and D.
These data suggest that over-expressed WT and par-
ticularly E2 vimentin sequester IRBIT and may impair its
function, while the A2 mutant has a relatively mild in-
hibitory effect. This is in accordance with the results in
Figures 3 and 4 showing phosphorylated vimentin trap-
ping IRBIT in perinuclear structures more efficiently
than the phospho-resistant, A2 form.
Conclusions
In the present study, we introduce vimentin as a modifier
of mutant Htt aggregation. Vimentin over-expression
increased and the knock-down reduced the mutant Htt
aggregation in Neuro2a cells. ROCK inhibitor Y-27632
inhibited vimentin phosphorylation at Ser71 and Ser38
and reduced the promoting effect of vimentin on mu-
tant Htt aggregation. We found that interaction of
IRBIT with IP3R1 is affected by vimentin and that the
extent of this effect is dependent on the amino acids at
positions 71 and 38. Accordingly, vimentin sequestered
IRBIT in cage-like structures resembling aggresomes
with the phosphomimetic E2 vimentin mutant traping
IRBIT almost exclusively in perinuclear inclusions. The
unphosphorylated A2 mutant expression, on the other
hand, did not result in cage formation and IRBIT se-
questration even when UPS was inhibited. We showed
the relevance of vimentin-IRBIT axis in polyQ aggrega-
tion regulation in 150Q Neuro2a cells, where reduced
levels of IRBIT enhanced, and increased levels of IRBIT
decreased mutant Htt inclusion formation. These effects
were modified by vimentin levels and mutations at Ser71
and Ser38. Although it has been speculated that aggre-
somes fulfill a protective role in polyQ diseases pathome-
chanism [47], based on our study we hypothesize that this
function might depend on the dynamics of aggresome for-
mation. If normal cellular proteins are sequestered too fast
to the aggresomes without a sufficient time period for the
cell to replace them or adapt to this state, it may contri-
bute to cell death.
Figure 5 IRBIT modifies inclusion formation in 150Q Neuro2a cells. A. 48 hrs after transfection of control or IRBIT siRNA and RFP or tested
RFP-vimentin forms, cells were induced for 24 hrs, fixed, and analyzed by ArrayScan. *p= 0.028, **p= 0.0008, ***p= 0.00005, ****p= 0.00004,
^p= 0.0018, ^^p= 0.0021, ^^^p= 0.00034, #p= 0.0007, ##p= 0.0004, ###p= 0.00002, }p= 0.016, }}p= 0.0001. B. Images generated and analyzed by
ArrayScan representing each experimental condition in A. Green, tNHtt-150Q-EGFP; blue, Hoechst 33258. Magnification, 20x. C. Cells were co-
transfected with mock or flag-IRBIT and RFP or tested RFP-vimentin forms and induced for 24 hrs before analyzed by ArrayScan. *p= 0.042,
**p= 0.0002, ***p= 0.049, ^p= 0.0002, ^^p= 0.0099, ^^^p= 0.00013, #p= 0.00005, ##p= 0.015, ###p= 0.00009, ####p= 0.0008, #####p= 0.0005,
######p= 0.0092, }p= 0.0026, }}p= 0.0016. D. Images generated and analyzed by ArrayScan representing each experimental condition in C. Green,
tNHtt-150Q-EGFP; blue, Hoechst 33258. Magnification, 20x. Bars in A and C represent relative mean values ± s.d. from four independent
experiments, with levels of inclusion formation under control conditions normalized to a value of 1.
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model for the modifying effect of vimentin on polyQ
protein accumulation and inclusion formation: vimentin
and preferentially its phosphorylated form (at Ser71
and Ser38) promote polyQ aggregation by sequestering
IRBIT in perinuclear inclusions and preventing its
interaction with IP3R1 (Figure 6A). Increased activity of
IP3R1 in polyQ diseases models has been previously
reported to contribute to cytotoxicity of the pathogenic
misfolded proteins [25,26,28] and knock-down or chem-
ical inhibition of IP3R1 reduced mutant Htt aggregation
[27]. The therapeutic potential of ROCK inhibitors
may thus be partly mediated by decreased vimentin
phosphorylation leading to reduction of IP3R1 activity
(Figure 6B). Importantly, activation of vimentin expres-
sion was shown in mature neurons affected by neu-
rodegenerative or traumatic insults [15,16]. Reduction
of vimentin levels and/or phosphorylation appears as
a promising therapeutic strategy for HD and other
polyQ diseases.Methods
Materials
The ROCK inhibitor Y-27632 was from Sigma and
MG132 (Z-Leu-Leu-Leu-aldehyde) from Wako Chemi-
cals. Fluorescent nucleic acid stain Hoechst 33258 was
from Molecular Probes. Mouse monoclonal antibody
recognizing expanded polyQ tract, 1C2, and rat mono-
clonal anti-β-tubulin were obtained from Chemicon.
Mouse monoclonal anti-vimentin antibody antibody was
from Sigma. Rat monoclonal anti-phospho-vimentin
(Ser71) and (Ser38) antibodies, and mouse monoclonal
anti-GFP and anti-RFP antibodies were purchased from
MBL. Mouse monoclonal anti-IP3R1 antibody KM1112,
rat anti-IP3R1 antibody 10A6 and rabbit anti-IRBIT
were generated as reported previously [22,48,49].
Plasmids
Plasmids encoding the truncated N-terminal of human
huntingtin (tNHtt) with 16, 60, and 150 glutamine re-
peats were introduced in pEGFP-N1 vector as previously
Figure 6 Schematic representation of the proposed mechanism of the vimentin effect on mutant Htt aggregation. A. In HD, mutant Htt
and dopamine stimulation may activate ROCK, which in turn phosphorylates vimentin at Ser71 and Ser38 leading to IRBIT sequestration, reduced
interaction of IRBIT with IP3R1, and activation of IP3R1. Mutant Htt expression and aggregation may increase aggresome formation enhancing
IRBIT sequestration. B. Blocking vimentin phosphorylation by ROCK inhibitors may lead to reduced IRBIT sequestration by vimentin and
consequently to decreased accumulation and aggregation of the pathogenic polyQ protein.
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with 60Q and 150Q for transient transfection, tNHtt-
polyQ-EGFP fragment was cut from pIND tNHtt-polyQ-
EGFP [51] with HindIII-XbaI digestion, and the resulting
fragment was inserted into pcDNA3.1-v5/His plasmid.
The monomeric red fluorescence protein (RFP) plasmid
preparation has previously been described [52]. Construc-
tion of N-terminally Flag-tagged IRBIT was described
previously [23].
Mouse vimentin was amplified from mouse cDNA
library using 5’-TCCCGAATTCAAGCTTCCACCATGT
CTACCAGGTCTGTGTCC-3’ as forward and 5’-AAA
CACCGGATCCGGTTCAAGGTCATCGTGATGCTG-3’
as reverse primer. The amplified vimentin cDNA frag-
ment was inserted into HindIII/BamHI site of the
pmRFP-C1 plasmid and named RFP-vimentin.
The mutations in RFP-vimentin were introduced using
QuikChangeW Site-Directed Mutagenesis Kit (Stratagene).
To generate phospho-mimetic (E2) and unphosphorylated
(A2) mutants, following primers were used to exchange
Ser71 and Ser38 to Glu or Ala: Ser71Glu: forward:
5`-GTGCGCCTGCGGGAAAGCGTGCCGGGCTG-3`
and reverse, 5`-CAGCCCGGCACGCTTTCCCGCAGGC
GCAC-3` Ser38Glu: forward, 5`- CACGTCCACACGCA
CCTACGAACTGGGCAGCGCAC-3` and reverse, 5`- GT
GCGCTGCCCAGTTCGTAGGTGCGTGTGGACGTG-3;
Ser71Ala: forward, 5`-GTGCGCCTGCG GGCTAGCGTGCCGGGCTG-3` and reverse, 5`-CAGCCCGGCACG
CTAGCCCGCAGGCGCAC-3`. Ser38Ala: forward, 5`-
CACGTCCACACGCACCTACGCTCTGGGCAGCGC
AC-3` and reverse, 5`- GTGCGCTGCCCAGAGCGTAG
GTGCGTGTGGACGTG-3`.
Cell culture, transient transfection and treatments
Mouse neuroblastoma (Neuro2a) and human cervical car-
cinoma cells (HeLa) cells were maintained in Dulbecco's
modified Eagle's medium (Sigma) supplemented with 10%
heat-inactivated fetal bovine serum (Sigma), 100 U/ml
penicillin and 100 μg/ml streptomycin (Invitrogen) at
37°C in an humidified atmosphere containing 5% CO2. Es-
tablishment of stable Neuro2a cell lines with the ecdysone-
inducible mammalian expression system (Invitrogen), that
express tNHtt-EGFP-16Q (16Q Neuro2a cells), tNHtt-
60Q-EGFP (60Q Neuro2a cells) and tNHtt-EGFP-150Q
(150Q Neuro2a cells) has been described earlier [50,51].
Neuro2a cells were differentiated with 5 mM dbcAMP
(N6,2'-O-dibutyryladenosine-3',5'-cyclic monophosphate so-
dium salt) and induced to express tNHtt-polyQ-EGFP with
2 μM ponasterone A (Invitrogen).
RFP-vimentin was transfected into Neuro2a/FRT cells
[53]. The stably transfected cells resistant to treatment with
400 μg/ml G418 (Calbiochem), were sub-cloned twice.
All transient transfections were performed when the
cells reached 70-80% confluence with Lipofectamine
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manufacturer’s instruction.
RNA interference
The non-silencing control, vimentin and IP3R1 shRNAs
were obtained from Open Biosystems. Plasmids were
transfected into cells using Lipofectamine 2000. Neuro2a
cells were induced 48 hrs later. Stealth siRNA specific for
IRBIT and scrambled control were obtained from Invitro-
gen. 20 μM siRNA stock solutions were used for transfec-
tion to Neuro2a cells by Lipofectamine 2000 and after
48 hrs, cells were transfected again with RFP or RFP-
vimentin. Cells were used for experiments 24 hrs later.
ArrayScan quantification
For the quantification of the inclusions, cells were grown
in 24-well plates, fixed in 4% paraformaldehyde, washed
and incubated with Hoechst 33258 at 1/1000 dilution in
PBS. Cells were analyzed by ArrayScanWVTI High Con-
tent Screening (HCS) Reader (Cellomics) using Target
Activation BioApplication (TABA) as described earlier
[37]. TABA analyzes images acquired by a HCS Reader
and provides measurements of the intracellular fluores-
cence intensity and localization on a cell-by-cell basis. In
each well, at least 10,000 cells were counted and quanti-
fied for the presence of the inclusions. Scanning was
performed with triplicate or quadruplicate in each ex-
perimental condition.
Cell death assay
For quantification of cell viability, 5 μg/ml each of
Hoechst 33342 and PI were added to differentiated and
induced Neuro2a cells. After 10 min at 37°C, the PI-
positive cells were quantified with ArrayScan.
HeLa cells lysis and immunoprecipitation experiments
Twenty four hours after transfection, HeLa cells were
lysed in buffer containing 50 mM Hepes (pH 7.5),
150 mM NaCl, 2 mM EDTA, Complete protease inhibitor
cocktail (Roche) and 0.5% NP40 (Sigma) for 30 min on
ice and briefly sonicated. Cell lysates were centrifuged at
10,000 g for 30 min at 4°C. Supernatants were rotated for
2 hrs at 4°C with IP3R1 antibody. Immuno-bound com-
plexes were isolated by incubation with 20 μl of protein
G-Sepharose 4B beads (50% slurry) (Amersham) for 2 hrs
at 4°C. Precipitated proteins were eluted with SDS-PAGE
sample buffer and analyzed by western blotting with
appropriate antibodies.
Western blotting
Cells were washed twice with ice-cold PBS, scraped, and
resuspended in lysis buffer containing 0.5% Triton
X-100 in PBS (pH 7.4), 0.5 mM phenylmethylsulfonyl
fluoride and Complete protease inhibitor cocktail. Afterincubating on ice for 30 min, lysates were briefly soni-
cated. Protein concentrations were determined accord-
ing to the method of Bradford using Bio-Rad protein
assay reagent (Bio-Rad) and the Western blot procedure
was performed as described previously [37]. Images were
quantified using Multi Gauge software (Fujifilm).
Confocal microscopy
Neuro2a cells were grown, transfected and treated in 4-
well chamber slides. Cells were processed according to
two protocols. Firstly, permeabilization and fixation
protocol was used to wash out cytosolic proteins not
bound to membranes or cytoskeleton. Cells were washed
with PBS followed incubation in ice-cold pre-extraction
buffer containing 80 mM PIPES (pH 7.2), 1 mM MgCl2,
1 mM EGTA, 4% PEG 6000 and 0.1% saponin on ice
for 10 min. Samples were rinsed with PBS and fixed
with 4% formaldehyde in PBS for 15 min at room
temperature. Secondly, standard procedure was used
with cell fixation in 4% paraformaldehyde/PBS and
permeabilization with 0.1% Triton X-100/PBS. Samples
were incubated with anti-IRBIT antibody for 1 hr at
room temperature, washed, incubated for 1 hr with
Alexa Fluor 488 anti-rabbit secondary antibody (Invitro-
gen) and mounted with Vectashield mounting medium
containing DAPI. Inducible tNHtt-polyQ-EGFP Neuro2a
transfected with RFP or RFP-vimentin and Neuro2a cells
stably expressing RFP-vimentin transfected with tNHtt-
16Q-EGFP or tNHtt-60Q-EGFP were fixed using 4%
paraformaldehyde/PBS, and mounted with Vectashield
mounting medium containing DAPI. Images were gener-
ated using confocal microscope (Leica).
Statistical analysis
Unpaired student’s t-test for comparison between two
samples was used. One-way ANOVA Fisher's test fol-
lowed by Tukey's HSD test or two-way ANOVA test
with pair-wise contrast was performed. The data was
generated with XLSTAT software. We considered the
difference between comparisons to be significant when
p < 0.05 for all statistical analyses.
Additional file
Additional file 1: Figure S1. Confocal images show distribution of
pathogenic 150Q tNHtt (green) and RFP-vimentin (red) in inducible
tNHtt-150Q-EGFP Neuro2a cells. Note the cages formed by vimentin
around the 150Q tNHtt aggregates. Nuclei were stained with DAPI (blue).
Scale bar, 10 μm.
Abbreviations
HD: Huntington’s Disease; Htt: Huntingtin; polyQ: Polyglutamine; IP3: Inositol
1,4,5-trisphosphate; IP3R1: IP3 receptor type 1; IRBIT: IP3R1-interacting protein
released with IP3; UPS: Ubiquitin proteasome system; IF: Intermediate
filament; WT: Wild-type; D2R: Dopamine D2 receptor; ROCK: Rho-associated
kinase; PRK-2: Protein kinase C-related protein kinase-2; tNHtt: Truncated
Bauer et al. Molecular Neurodegeneration 2012, 7:43 Page 11 of 12
http://www.molecularneurodegeneration.com/content/7/1/43N-terminal of human Htt; EGFP: Enhanced green fluorescent protein;
RFP: Red fluorescence protein.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
POB and RH raised the hypothesis and designed the experiments.
Experimental work was performed by POB, RH, AG and MK RFP-vimentin
construct and the stable RFP-Vimentin Neuro2a cell line was prepared by
GM The results were analyzed by POB, RH, AG, KM and NN The
manuscript was written by POB, RH and NN. All authors discussed the
results and commented on the manuscript.
Acknowledgements
This work was partly supported by a Grant from Japan Society for the
Promotion of Science (JSPS). P.O.B. and R.H were JSPS postdoctoral fellows.
This work was supported by Grant-in-Aid from the Ministry of Education,
Culture, Sports, Science, and Technology of Japan for N.N. (22110004 and
22240037), by Core Research for Evolutional Science and Technology from
Japan Science and Technology Agency for N.N., and by a Grant in-Aid for
the Research on Measures for Ataxic Diseases from the Ministry of Health,
Welfare and Labor for N.N.
Author details
1Laboratory for Structural Neuropathology, Brain Science Institute, RIKEN, 2-1
Hirosawa, Wako-shi, Saitama 351-0198, Japan. 2Laboratory for Developmental
Neurobiology, Brain Science Institute, RIKEN, 2-1 Hirosawa, Wako-shi, Saitama
351-0198, Japan. 3Calcium Oscillation Project, ICORP-SORST, Japan Science
and Technology Agency (JST), 4-1-8 Honcho, Kawaguchi, Saitama 332-0012,
Japan. 4Present address: Neuro-Oncology Branch, National Cancer Institute,
National Institute of Neurological Disorders and Stroke, National Institutes of
Health, 37 Convent Drive, Bethesda, MD 20892, USA. 5Present address:
Institute of Biochemistry, Nutrition and Health Protection, Department of
Biochemistry and Microbiology, Faculty of Chemical and Food Technology,
Slovak University of Technology, Radlinskeho 9, 812 37 Bratislava, Slovakia.
Received: 16 May 2012 Accepted: 6 August 2012
Published: 28 August 2012
References
1. Myers RH: Huntington's disease genetics. NeuroRx 2004, 1:255–262.
2. Orr HT, Zoghbi HY: Trinucleotide repeat disorders. Annu Rev Neurosci 2007,
30:575–621.
3. The Huntington’s Disease Collaborative Research Group: A novel gene
containing a trinucleotide repeat that is expanded and unstable on
Huntington's disease chromosomes. Cell 1993, 72:971–983.
4. DiFiglia M, Sapp E, Chase KO, Davies SW, Bates GP, Vonsattel JP, Aronin N:
Aggregation of huntingtin in neuronal intranuclear inclusions and
dystrophic neurites in brain. Science 1997, 277:1990–1993.
5. Saudou F, Finkbeiner S, Devys D, Greenberg ME: Huntingtin acts in the
nucleus to induce apoptosis but death does not correlate with the
formation of intranuclear inclusions. Cell 1998, 95:55–66.
6. Landles C, Bates GP: Huntingtin and the molecular pathogenesis of
Huntington's disease, Fourth in molecular medicine review series. EMBO
Rep 2004, 5:958–963.
7. Bauer PO, Nukina N: The pathogenic mechanisms of polyglutamine diseases
and current therapeutic strategies. J Neurochem 2009, 110:1737–1765.
8. Oliveira JMA, Jekabsons MB, Chen S, Lin A, Rego CA, Goncalves J, Ellerby
LM, Nicholls DJ: Mitochondrial dysfunction in Huntington’s disease: the
bioenergetics of isolated and in situ mitochondria from transgenic mice.
J Neurochem 2007, 101:241–249.
9. Oliveira JMA: Mitochondrial bioenergetics and dynamics in Huntington’s
disease: tripartite synapses and selective striatal degeneration. J Bioenerg
Biomembr 2010, 42:227–234.
10. Franke WW, Schmid E, Winter S, Osborn M, Weber K: Widespread
occurrence of intermediate-sized filaments of the vimentin-type in
cultured cells from diverse vertebrates. Exp Cell Res 1979, 123:25–46.
11. Paulin D, Jakob H, Jacob F, Weber K, Osborn M: In vitro differentiation of
mouse teratocarcinoma cells monitored by intermediate filament
expression. Differentiation 1982, 22:90–99.12. Bignami A, Raju T, Dahl D: Localization of vimentin, the nonspecific
intermediate filament protein, in embryonal glia and in early
differentiating neurons, In vivo and in vitro immunofluorescence study
of the rat embryo with vimentin and neurofilament antisera. Dev Biol
1982, 91:286–295.
13. Franke WW, Schmid E, Osborn M, Weber K: Intermediate-sized filaments of
human endothelial cells. J Cell Biol 1979, 81:570–580.
14. Izmiryan A, Franco CA, Paulin D, Li Z, Xue Z: Synemin isoforms during
mouse development: multiplicity of partners in vascular and neuronal
systems. Exp Cell Res 2009, 315:769–783.
15. Yen SH, Gaskin F, Fu SM: Neurofibrillary tangles in senile dementia of the
Alzheimer type share an antigenic determinant with intermediate
filaments of the vimentin class. Am J Pathol 1983, 113:373–381.
16. Levin EC, Acharya NK, Sedeyn JC, Venkataraman V, D'Andrea MR, Wang HY,
Nagele RG: Neuronal expression of vimentin in the Alzheimer's disease
brain may be part of a generalized dendritic damage-response
mechanism. Brain Res 2009, 1298:194–207.
17. Wigley WC, Fabunmi RP, Lee MG, Marino CR, Muallem S, DeMartino GN,
Thomas PJ: Dynamic association of proteasomal machinery with the
centrosome. J Cell Biol 1999, 145:481–490.
18. Ward CL, Omura S, Kopito RR: Degradation of CFTR by the ubiquitin-
proteasome pathway. Cell 1995, 83:121–127.
19. Johnston JA, Ward CL, Kopito RR: Aggresomes: a cellular response to
misfolded proteins. J Cell Biol 1998, 143:1883–1898.
20. Waelter S, Boeddrich A, Lurz R, Scherzinger E, Lueder G, Lehrach H, Wanker
EE: Accumulation of mutant huntingtin fragments in aggresome-like
inclusion bodies as a result of insufficient protein degradation. Mol Biol
Cell 2001, 12:1393–1407.
21. Shimohata T, Sato A, Burke JR, Strittmatter WJ, Tsuji S, Onodera O:
Expanded polyglutamine stretches form an 'aggresome'. Neurosci Lett
2002, 323:215–218.
22. Ando H, Mizutani A, Matsu-ura T, Mikoshiba K: IRBIT, a novel inositol
1,4,5-trisphosphate (IP3) receptor-binding protein, is released from the
IP3 receptor upon IP3 binding to the receptor. J Biol Chem 2003,
278:10602–10612.
23. Ando H, Mizutani A, Kiefer H, Tsuzurugi D, Michikawa T, Mikoshiba K: IRBIT
suppresses IP3 receptor activity by competing with IP3 for the common
binding site on the IP3 receptor. Mol Cell 2006, 22:795–806.
24. Devogelaere B, Beullens M, Sammels E, Derua R, Waelkens E, Van Lint J,
Parys JB, Missiaen L, Bollen M, De Smedt H: Protein phosphatase-1 is a
novel regulator of the interaction between IRBIT and the inositol 1,4,5-
trisphosphate receptor. Biochem J 2007, 407:303–311.
25. Tang TS, Tu H, Chan EY, Maximov A, Wang Z, Wellington CL, Hayden MR,
Bezprozvanny I: Huntingtin and huntingtin-associated protein 1 influence
neuronal calcium signaling mediated by inositol-(1,4,5) triphosphate
receptor type 1. Neuron 2003, 39:227–239.
26. Bezprozvanny I: Inositol 1,4,5-tripshosphate receptor, calcium signaling
and Huntington's disease. Subcell Biochem 2007, 45:323–335.
27. Bauer PO, Hudec R, Ozaki S, Okuno M, Ebisui E, Mikoshiba K, Nukina N:
Genetic ablation and chemical inhibition of IP3R1 reduce mutant
huntingtin aggregation. Biochem Biophys Res Commun 2011, 416:13–17.
28. Tang TS, Slow E, Lupu V, Stavrovskaya IG, Sugimori M, Llinás R, Kristal BS,
Hayden MR, Bezprozvanny I: Disturbed Ca2+ signaling and apoptosis of
medium spiny neurons in Huntington's disease. Proc Natl Acad Sci USA
2005, 102:2602–2607.
29. Goto H, Kosako H, Tanabe K, Yanagida M, Sakurai M, Amano M, Kaibuchi K,
Inagaki M: Phosphorylation of vimentin by Rho-associated kinase at a
unique amino-terminal site that is specifically phosphorylated during
cytokinesis. J Biol Chem 1998, 273:11728–11736.
30. Nakamura Y, Hashimoto R, Amano M, Nagata K, Matsumoto N, Goto H,
Fukusho E, Mori H, Kashiwagi Y, Kudo T, Inagaki M, Takeda M: Localized
phosphorylation of vimentin by rho-kinase in neuroblastoma N2a cells.
Genes Cells 2000, 5:823–837.
31. Ishizaki T, Maekawa M, Fujisawa K, Okawa K, Iwamatsu A, Fujita A, Watanabe
N, Saito Y, Kakizuka A, Morii N, Narumiya S: The small GTP-binding protein
Rho binds to and activates a 160 kDa Ser/Thr protein kinase
homologous to myotonic dystrophy kinase. EMBO J 1996, 15:1885–1893.
32. Matsui T, Amano M, Yamamoto T, Chihara K, Nakafuku M, Ito M, Nakano T,
Okawa K, Iwamatsu A, Kaibuchi K: Rho-associated kinase, a novel serine/
threonine kinase, as a putative target for small GTP binding protein Rho.
EMBO J 1996, 15:2208–2216.
Bauer et al. Molecular Neurodegeneration 2012, 7:43 Page 12 of 12
http://www.molecularneurodegeneration.com/content/7/1/4333. Riento K, Ridley AJ: Rocks: multifunctional kinases in cell behavior. Nat Rev
Mol Cell Biol 2003, 4:446–456.
34. Pollitt SK, Pallos J, Shao J, Desai UA, Ma AA, Thompson LM, Marsh JL,
Diamond MI: A rapid cellular FRET assay of polyglutamine aggregation
identifies a novel inhibitor. Neuron 2003, 40:685–694.
35. Shao J, Welch WJ, Diamond MI: ROCK and PRK-2 mediate the inhibitory
effect of Y-27632 on polyglutamine aggregation. FEBS Lett 2008,
582:1637–1642.
36. Shao J, Welch WJ, Diprospero NA, Diamond MI: Phosphorylation of profilin
by ROCK1 regulates polyglutamine aggregation. Mol Cell Biol 2008,
28:5196–5208.
37. Bauer PO, Wong HK, Oyama F, Goswami A, Okuno M, Kino Y, Miyazaki H,
Nukina N: Inhibition of Rho kinases enhances the degradation of mutant
huntingtin. J Biol Chem 2009, 284:13153–13164.
38. Bauer PO, Nukina N: Enhanced degradation of mutant huntingtin by rho
kinase inhibition is mediated through activation of proteasome and
macroautophagy. Autophagy 2009, 5:747–748.
39. Tang TS, Chen X, Liu J, Bezprozvanny I: Dopaminergic signaling and
striatal neurodegeneration in Huntington’s Disease. J Neurosci 2007,
27:7899–7910.
40. Deyts C, Galan-Rodriguez B, Martin E, Bouveyron N, Roze E, Charvin D,
Caboche J, Bétuing S: Dopamine D2 receptor stimulation potentiates
polyQ-Huntingtin-induced mouse striatal neuron dysfunctions via Rho/
ROCK-II activation. PLoS One 2009, 4:e8287.
41. Li M, Huang Y, Ma AA, Lin E, Diamond MI: Y-27632 improves rotarod
performance and reduces huntingtin levels in R6/2 mice. Neurobiol Dis
2009, 3:413–420.
42. Ivaska J, Pallari HM, Nevo J, Eriksson JE: Novel functions of vimentin in cell
adhesion, migration, and signaling. Exp Cell Res 2007, 313:2050–2062.
43. Heimfarth L, Loureiro SO, Reis KP, de Lima BO, Zamboni F, Gandolfi T, Narvaes
R, da Rocha JB, Pessoa-Pureur R: Cross-talk among intracellular signaling
pathways mediates the diphenyl ditelluride actions on the hippocampal
cytoskeleton of young rats. Chem Res Toxicol 2011, 24:1754–1764.
44. Minase T, Ishima T, Itoh K, Hashimoto K: Potentiation of nerve growth
factor-induced neurite outgrowth by the ROCK inhibitor Y-27632: a
possible role of IP3 receptors. Eur J Pharmacol 2010, 648:67–73.
45. Toth C, Shim SY, Wang J, Jiang Y, Neumayer G, Belzil C, Liu WQ, Martinez J,
Zochodne D, Nguyen MD: Ndel1 promotes axon regeneration via
intermediate filaments. PLoS One 2008, 3:e2014.
46. Mikoshiba K: IP3 receptor/Ca2+ channel: from discovery to new signaling
concepts. J Neurochem 2007, 102:1426–1446.
47. Taylor JP, Tanaka F, Robitschek J, Sandoval CM, Taye A, Markovic-Plese S,
Fischbeck KH: Aggresomes protect cells by enhancing the degradation of
toxic polyglutamine-containing protein. Hum Mol Genet 2003, 12:749–757.
48. Sugiyama T, Furuya A, Monkawa T, Yamamoto-Hino M, Satoh S, Ohmori K,
Miyawaki A, Hanai N, Mikoshiba K, Hasegawa M: Monoclonal antibodies
distinctively recognizing the subtypes of inositol 1,4,5-trisphosphate
receptor: application to the studies on inflammatory cells. FEBS Lett 1994,
354:149–154.
49. Maeda N, Niinobe M, Mikoshiba K: A cerebellar Purkinje cell marker P400
protein is an inositol 1,4,5-trisphosphate (InsP3) receptor protein. Purification
and characterization of InsP3 receptor complex. EMBO J 1990, 9:61–67.
50. Wang GH, Mitsui K, Kotliarova S, Yamashita A, Nagao Y, Tokuhiro S,
Iwatsubo T, Kanazawa I, Nukina N: Caspase activation during apoptotic
cell death induced by expanded polyglutamine in N2a cells. Neuroreport
1999, 10:2435–2438.
51. Zemskov EA, Jana NR, Kurosawa M, Miyazaki H, Sakamoto N, Nekooki M,
Nukina N: Pro-apoptotic protein kinase C delta is associated with
intranuclear inclusions in a transgenic model of Huntington's disease.
J Neurochem 2003, 87:395–406.
52. Machida Y, Okada T, Kurosawa M, Oyama F, Ozawa K, Nukina N: rAAV-
mediated shRNA ameliorated neuropathology in Huntington disease
model mouse. Biochem Biophys Res Commun 2006, 343:190–197.
53. Matsumoto G, Wada K, Okuno M, Kurosawa M, Nukina N: Serine 403
phosphorylation of p62/SQSTM1 regulates selective autophagic
clearance of ubiquitinated proteins. Mol Cell 2011, 44:279–289.
doi:10.1186/1750-1326-7-43
Cite this article as: Bauer et al.: ROCK-phosphorylated vimentin modifies
mutant huntingtin aggregation via sequestration of IRBIT. Molecular
Neurodegeneration 2012 7:43.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
